Interest is gathering on the insurance reimbursement of Omjjara, a targeted therapy for myelofibrosis.

According to industry sources, GSK Korea is preparing to submit a reimbursement application for its myelofibrosis drug, Ojjaara (momelotinib) in Korea. The company is expected to submit its application next month (December). 

Specifically, the indication the company will apply for reimbursement is for the “treatment of myelofibrosis in intermediate- or high-risk adults with anemia.” The drug’s approved indication includes both primary myelofibrosis and myelofibrosis post-polycythemia vera (PV) and post-essential thrombocythemia (ET).

Unlike existing drugs that ac